Promising HPV Vaccine Receives Development Funding from the National Cancer Institute
the Cancer Therapy Advisor take:
The National Cancer Institute (NCI) has funded $3.5 million for the development of a new human papillomavirus (HPV) vaccine at the MedUni Vienna.
The funding from NCI will allow researchers at MedUni Vienna to begin developing the clinical trials that are needed to license the vaccine. The vaccine has already shown (via laboratory studies) to be significantly effective against a wide range of high- and low-risk types of HPV compared with HPV vaccines that are currently available. The vaccine is also aimed at protecting recipients from developing strains of HPV that lead to skin warts. Skin warts are not only a cosmetic issue for patients, but they also pose a serious health risk to individuals who are immunosuppressed.
In addition, the manufacturing of this vaccine is more economical and technically easier because it contains a single antigen (HPV16 RG1-VPL) compared with currently vaccines that contain two to four antigens. The research team, led by Reinhard Kirnbauer, MD, received the funding through the NCI’s PREVENT Cancer Program. The new vaccine will be created under the United States’ current Good Manufacturing Practice guidelines, meaning that the quality of production sequences and environments will be ensured to the United States’ standards.
After production is complete, the vaccine will be prepared for licensing from the U.S. Food and Drug Administration as an investigational new drug, an essential component in the process of having the vaccine begin early phase human clinical trials, which are already being planned.
The National Cancer Institute has funded $3.5 million for the development of a new HPV vaccine.
The National Cancer Institute in the USA is supporting the new vaccine developed at the MedUni Vienna against the human papillomavirus (HPV) with at least US$ 3.5 million. This is a major success for the developers and means that the foundations can now be laid for the clinical trials needed for licensing as a vaccine. The National Cancer Institute (NCI) of the US National Institutes of Health (NIH) is supporting further clinical development of a new, improved, next-generation HPV vaccine.
The vaccine was developed by a team led by Reinhard Kirnbauer from the Division of Immunodermatology at the MedUni Vienna in collaboration with Christina Schellenbacher and support from the Austrian Science Fund (FWF) and Vienna Science and Technology Fund (WWTF). The new vaccine had already demonstrated its excellent efficacy in a pre-clinical study in 2013.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer